| 4.61 -0.36 (-7.24%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.74 |
1-year : | 7.66 |
| Resists | First : | 5.77 |
Second : | 6.55 |
| Pivot price | 5.43 |
|||
| Supports | First : | 4.51 |
Second : | 3.75 |
| MAs | MA(5) : | 4.85 |
MA(20) : | 5.45 |
| MA(100) : | 7.87 |
MA(250) : | 123.43 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 7.7 |
D(3) : | 7.1 |
| RSI | RSI(14): 32.9 |
|||
| 52-week | High : | 594 | Low : | 4.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HIND ] has closed above bottom band by 9.1%. Bollinger Bands are 45.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 146 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.5 - 5.53 | 5.53 - 5.56 |
| Low: | 4.45 - 4.48 | 4.48 - 4.5 |
| Close: | 4.57 - 4.61 | 4.61 - 4.66 |
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
Wed, 19 Nov 2025
Vyome Holdings Inc. Reports Post-Merger Financials - TipRanks
Tue, 18 Nov 2025
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing - Business Wire
Tue, 04 Nov 2025
Vyome Holdings Announces Results of Annual Shareholder Meeting - Business Wire
Wed, 17 Sep 2025
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Stocktwits
Wed, 17 Sep 2025
Vyome Holdings (HIND) Skyrockets Over 50% on Breakthrough Uveitis Treatment News - RagingBull
Wed, 17 Sep 2025
HIND Stock: Growth or Bubble? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 43.3 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 73 (K) |
| Shares Short P.Month | 204 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -27.14 |
| Profit Margin | 0 % |
| Operating Margin | -649 % |
| Return on Assets (ttm) | -43.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 46.9 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -21.96 |
| PEG Ratio | 0 |
| Price to Book value | -0.17 |
| Price to Sales | 65.79 |
| Price to Cash Flow | -29.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|